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Parenteral administration of 
factor Xa/IIa inhibitors limits 
experimental aortic aneurysm and 
atherosclerosis
Corey S. Moran1,*, Sai-Wang Seto2,*, Smriti M. Krishna1, Surabhi Sharma1, Roby J. Jose1, 
Erik Biros1, Yutang Wang3, Susan K. Morton1 & Jonathan Golledge1,4
Intraluminal thrombus is a consistent feature of human abdominal aortic aneurysm (AAA). Coagulation 
factor Xa (FXa) catalyses FII to thrombin (FIIa). We examined the effect of FXa/FIIa inhibition on 
experimental aortic aneurysm in apolipoprotein E-deficient (ApoE−/−) mice infused with angiotensin 
II (AngII). The concentration of FXa within the supra-renal aorta (SRA) correlated positively with 
SRA diameter. Parenteral administration of enoxaparin (FXa/IIa inhibitor) and fondaparinux (FXa 
inhibitor) over 14 days reduced to severity of aortic aneurysm and atherosclerosis in AngII-infused 
ApoE−/− mice. Enteral administration of the FIIa inhibitor dabigatran had no significant effect. Aortic 
protease-activated receptor (PAR)-2 expression increased in response to AngII infusion. Fondaparinux 
reduced SRA levels of FXa, FIIa, PAR-2, matrix metalloproteinase (MMP)2, Smad2/3 phosphorylation, 
and MOMA-2 positive cells in the mouse model. FXa stimulated Smad2/3 phosphorylation and 
MMP2 expression in aortic vascular smooth muscle cells (VSMC) in vitro. Expression of MMP2 in FXa-
stimulated VSMC was downregulated in the presence of a PAR-2 but not a PAR-1 inhibitor. These 
findings suggest that FXa/FIIa inhibition limits aortic aneurysm and atherosclerosis severity due to 
down-regulation of vascular PAR-2-mediated Smad2/3 signalling and MMP2 expression. Inhibition of 
FXa/FIIa may be a potential therapy for limiting aortic aneurysm.
Abdominal aortic aneurysm (AAA) is an age related degenerative disease which is present in ~5% of men and 
~1% of women aged ≥ 65 years and is an important cause of sudden death in older adults due to aortic rupture 
or associated athero-thrombotic events1. With the introduction of screening programs and the common use of 
abdominal imaging most AAAs are detected at a small size. Approximately 50% of small AAA (< 55 mm) even-
tually expand to a size where surgical intervention is required to prevent rupture1. There is currently no effective 
drug intervention to limit AAA growth2.
Activation of the coagulation cascade has long been implicated in cardiovascular events such as acute coro-
nary syndrome3,4. Anti-coagulant therapies are an important component of management of such events but are 
not routinely indicated in patients that have AAAs. Most human AAAs contain significant amounts of intralu-
minal thrombus (ILT), the volume of which has been shown to correlate strongly with AAA size and growth5,6. 
Human AAA thrombus contains high concentrations of pro-inflammatory cytokines, chemokines, inflamma-
tory cells and proteolytic enzymes which are all implicated in AAA pathogenesis7,8. Constant remodelling of the 
thrombus involving fibrin deposition and degradation is implicated in promoting aortic wall inflammation9.
Factor Xa (FXa) plays a central role in the coagulation cascade acting as the convergence point of the intrinsic 
and extrinsic coagulation pathways and catalyses the conversion of factor II (FII) to factor IIa (FIIa)10. Recent 
studies have suggested that both FXa and FIIa have a direct role in the pathogenesis of vascular diseases11,12. A 
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number of studies have suggested that inhibition of these clotting factors may reduce atherosclerosis progression 
in mouse models13–19, however the effect of anticoagulants on AAA progression has not been explored.
Direct cellular effects of FXa on the vasculature are mediated by the G-protein coupled protease-activated 
receptors (PAR), PAR-1 and PAR-220–22. Activation of these receptors promotes various cellular responses, such 
as smooth muscle cell migration, vascular remodelling, angiogenesis and inflammation, which are implicated 
in atherosclerosis and aneurysm pathogenesis. Expression of PAR-2 has been shown to be increased in rodent 
models of vascular injury and human atherosclerosis23–25. FXa has been shown to induce PAR-2, but not PAR-1 
expression, via a FIIa independent mechanism in human vascular smooth muscle cells, suggesting an independ-
ent role of FXa on PAR-2 signalling26. Activation of the Smad signalling pathway by FXa has been suggested as 
a potential therapeutic target for anticoagulants27, although the contribution of PAR-mediated Smad signalling, 
stimulated by FXa, to AAA and atherosclerosis pathogenesis has not been studied.
We administered enoxaparin (a low molecular weight heparin), fondaparinux (a synthetic, selective FXa 
inhibitor) or dabigatran (a direct FIIa inhibitor) to angiotensin II (AngII)-infused apolipoprotein E deficient 
(ApoE−/−) mice to assess the effect of anticoagulation therapy in an experimental model of aortic aneurysm that 
incorporates thrombus formation and atherosclerosis.
Results
AAA severity within the ApoE−/− mice infused with AngII correlated positively with aortic con-
centration of FXa. AngII infusion induces aortic aneurysm formation in ApoE−/− mice with the suprarenal 
aorta (SRA) being the common aortic site affected. FXa was abundantly expressed on Western blotting of proteins 
from large AAAs (Fig. S1). There was a strong positive correlation between the aortic levels of FXa and SRA diam-
eter (r = 0.936, P = 0.001; Fig. 1A).
Reduction of aortic aneurysm severity in mice administered enoxaparin. Enoxaparin (or vehicle) 
was administered via subcutaneous injection 14 days after commencement of AngII infusion and continued daily 
for the remainder of the infusion period. There were five fatalities due to aortic rupture in each of the two groups 
during the 14-day treatment period (see Supplementary Fig. S2). These aortas were successfully retrieved and 
included in final analyses. Administration of enoxaparin was associated with a significant decrease in aortic FXa 
activity compared to vehicle (0.004 ± 0.001 ng/μ g protein versus 0.65 ± 0.14 ng/μ g protein, respectively; P < 0.001; 
see Supplementary Fig. S3). Median maximum diameter of the SRA was significantly smaller in mice receiving 
enoxaparin compared to vehicle (Fig. 1B).
Reduction of aortic aneurysm severity in mice administered fondaparinux. Fondaparinux 
(or vehicle) was administered via subcutaneous injection 14 days after commencement of AngII infusion and 
continued daily for the remainder of the infusion period. Ultrasound measurements demonstrated that SRA 
expansion in response to AngII was reduced in mice receiving fondaparinux compared to controls (P = 0.034) 
(Fig. 1C). Aortas from all mice were harvested at the end of the study. Administration of fondaparinux signif-
icantly reduced the median level of aortic FXa compared to vehicle (0.77, 0.61–0.88 RDU/μ g protein vs 1.12, 
1.01–1.21 RDU/μ g protein; P = 0.008; Supplementary Fig. S3). The concentration of FIIa within the aorta was 
also reduced in mice receiving fondaparinux (1.37, 0.82–1.53 RDU/μ g protein vs 1.87, 1.72–1.91 RDU/μ g pro-
tein, respectively; P = 0.008; Supplementary Fig. S3). The median maximum SRA diameter in mice receiving 
fondaparinux was significantly reduced in comparison to controls (Fig. 1D). Intimal atherosclerotic lesion area 
within the aortic arch was assessed using Sudan IV staining. Mice receiving fondaparinux had significantly less 
mean positive Sudan IV staining area compared to the vehicle group (P = 0.025; Fig. 2).
Limited effect of oral administration of dabigatran on aortic aneurysm severity. Dabigatran 
etexilate (DE) was administered via medicated chow initiated 14 days after commencement of AngII infusion. 
Median concentration of FIIa within the aorta was reduced in mice receiving DE compared to controls (1.12, 
1.00–1.85 RDU/μ g protein vs 2.18, 2.07–2.24 RDU/μ g protein, respectively; P = 0.032; Supplementary Fig. S3). 
Median maximum SRA diameter remained comparable between mice receiving DE and mice receiving control 
chow throughout the intervention period as assessed by ultrasound (Supplementary Fig. S4), and confirmed 
by morphometric analysis at the end of the study (1.54, 1.32–1.95 mm vs 1.62, 1.37–2.38 mm, respectively; 
P = 0.684). Aortic arch Sudan IV staining area was smaller in mice administered dabigatran compared with 
mice receiving vehicle, however statistical significance was not demonstrated (16.95 ± 7.96% vs 20.30 ± 12.65%, 
respectively; n = 6; P = 0.474).
MMP2 and PAR-2 are downregulated within the SRA of mice administered fondaparinux. 
AngII infusion resulted in higher levels of PAR-2 protein within the SRA of ApoE−/− mice compared to 
saline-infused controls (median relative expression 1.262, inter-quartile range 1.108–1.339, n = 6 versus 0.742, 
0.560–0.815, n = 6, respectively, relative to Gapdh; P = 0.002). Gene expression for PAR-2 and MMP2 within 
the SRA of mice receiving fondaparinux was down-regulated 3- and 12-fold, respectively, compared to vehicle 
(Table 1). mRNA for MMP2 was reduced in mice receiving DE compared to vehicle but the difference was not 
statistically significant (Table 1). Gene expression for PAR-1 and MMP9 within the SRA was similar in mice 
receiving vehicle, fondaparinux, and DE (Table 1).
Fondaparinux reduced AngII-induced elastin degradation and inflammation within the 
aorta. Intramural thrombus formation within the SRA appeared to be reduced in mice administered 
fondaparinux compared to vehicle upon qualitative histological assessment (Fig. 3A). Elastin fibre fragmentation 
within the SRA also appeared less severe in mice receiving fondaparinux (Fig. 3B and C). The median ratio of 
aortic phosphorylated-to-total smad2/3 was significantly reduced in mice receiving fondaparinux compared to 
www.nature.com/scientificreports/
3Scientific RepoRts | 7:43079 | DOI: 10.1038/srep43079
vehicle (2.43, 2.27–2.55 vs 3.11, 3.10–3.58, respectively; P = 0.008; see Supplementary Fig. S5). Immunostaining 
for monocyte/macrophages (MOMA-2) within the adventitia and media of the SRA was significantly reduced in 
mice administered fondaparinux compared to vehicle (P = 0.032; Fig. 4).
Smad phosphorylation and upregulation of MMP2 in VSMC by FXa via PAR-2 in vitro. Incubation 
of human aortic VSMC with FXa (5–30 nM) induced a concentration-dependent increase in cellular Smad2/3 
phosphorylation over 24 hours (Fig. 5; Supplementary Fig. S5). Smad2/3 phosphorylation induced by FXa 
(30 nM) and Smad2/3 mRNA were down-regulated upon inhibition of PAR-2 (FSLLRY-NH2; 10 μ M), but were 
not affected in the presence of a PAR-1 antagonist (SCH79797; 10 μ M) (Table 2; Supplementary Fig. S5). Exposure 
of VSMC to FXa induced an increase in median mRNA expression of MMP2 (relative to GAPDH) from 0.57, 
0.49–0.64 to 0.86, 0.75–1.03 (P = 0.004). No significant change in mRNA expression for MMP9 was observed 
(0.58, 0.50–0.64 vs 0.63, 0.57–0.75; P = 0.238). Co-incubation of FXa-stimulated VSMC with the PAR-2 antago-
nist inhibited the up-regulation of MMP2 mRNA resulting in reduced supernatant levels of the protein (Table 2; 
Figure 1. Effect of enoxaparin and fondaparinux on AngII-induced aortic dilatation in ApoE−/−mice. 
(A) Relationship demonstrated between increasing SRA diameter and SRA concentration of FXa by Pearson 
correlation (r) coefficient; P = 0.001. (B) Maximum SRA diameter determined by morphometry at study end 
(day 28) in ApoE−/− mice receiving vehicle (control, n = 16) or enoxaparin (2.0 mg/kg/48 hrs, s.c., n = 16) for 
14 days. Data expressed as median and interquartile range (mm) with maximum and minimum data points 
(whiskers); *P = 0.008 by Mann-Whitney U test. (C) SRA diameter measured by ultrasound in mice receiving 
vehicle (solid line/grey bar) or fondaparinux (300 μ g/kg/day, s.c.; dashed line/white bar). Data expressed as 
median and interquartile range with maximum and minimum data points (whiskers); P = 0.034 for difference 
between groups by linear mixed-effects. (D) Maximum SRA diameter at study end (day 28) in ApoE−/− mice 
receiving vehicle (control, n = 11) or fondaparinux (300 μ g/kg/day, s.c, n = 13) for 14 days. Data expressed as 
median and interquartile range with maximum and minimum data points (whiskers); *P = 0.028 by Mann-
Whitney U test.
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see Supplementary Fig. S6). No effect on MMP2 mRNA or protein was observed in FXa-stimulated cells incu-
bated in the presence of the PAR-1 antagonist (Table 2; Supplementary Fig. S6).
Discussion
Intra-luminal thrombus (ILT) is present in most human AAAs and more rapid AAA growth is associated with 
larger ILT volume5,6. Although, the role of ILT in AAA is controversial, recent studies suggest that AAA thrombus 
is an important source of pro-inflammatory cytokines, reactive oxygen species and proteases implicated in AAA 
growth7–9,28. Circulating concentrations of thrombin-antithrombin III complex, D-dimer, and several clotting 
factors are elevated in AAA patients2,29. We examined the effect of the anticoagulants enoxaparin, fondaparinux, 
and dabigatran on growth of experimental aortic aneurysm in the AngII-infused ApoE−/− mouse model. Our 
results suggest that inhibition of FXa/FIIa limits the severity of aortic aneurysm and atherosclerosis in this model.
The presence of thrombus within the aortic wall is often seen in aortic aneurysms induced by AngII in the 
ApoE−/− mouse30. Development of intra-mural haematoma in this mouse model follows aortic dissection and a 
bleed into the vessel wall31, thus the presence of clotting factors within the aortic wall may not be unexpected. 
Enoxaparin is a low molecular weight heparin that complexes with anti-thrombin III (ATIII) to neutralise FXa, 
Figure 2. Reduced aortic arch atheroma in AngII-infused ApoE−/− mice administered fondaparinux. 
Reduced Sudan IV staining within the aortic arch of mice receiving fondaparinux (300 μ g/kg/day, s.c.) 
compared to vehicle. Data expressed as median and interquartile range with maximum and minimum data 
points (whiskers) for positive staining area relative to total specimen area (%); *P = 0.025 compared by Mann-
Whitney U test; n = 8.
Gene Vehicle Fondaparinux DE P
n 6 6 6
Par-1 1.06 (0.82–1.45) 1.16 (0.94–2.04) 1.70 (1.30–1.79) 0.136
Par-2 0.86 (0.72–1.09) 0.26 (0.20–0.32)* 0.99 (0.87–1.17) >0.001
Mmp2 2.19 (1.83–2.59) 0.17 (0.11–0.34)† 1.39 (0.73–2.82) >0.001
Mmp9 1.06 (1.01–1.16) 1.02 (1.00–1.06) 1.04 (1.01–1.09) 0.415
Table 1.  Effect of fondaparinux and dabigatran administered over 14 days on aortic PAR-1, PAR-2, and 
MMP2 mRNA within AngII-infused ApoE−/− mice. DE, dabigatran etexilate; Data expressed as median 
(interquartile range) gene expression relative to Gapdh; P, p-value for group comparison by Kruskal-Wallis test; 
*(P = 0.018) and †(P = 0.001) compared to vehicle and determined by Dunn’s post-hoc for multiple comparisons.
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and, to a lesser degree, FIIa activity32. Administration of enoxaparin in the current mouse model significantly 
reduced FXa activity within the aorta, although it is likely that inhibition of both FXa and FIIa activity contrib-
uted to the markedly decreased aortic response to AngII, suggesting that clotting factor activity within the aortic 
wall supported aortic dilatation in this model rather than being a consequence of it.
Factor IIa is produced by the enzymatic cleavage of prothrombin by FXa10. Unlike enoxaparin, the smaller 
low molecular weight heparin, fondaparinux, via complex with ATIII inactivates FXa but not FIIa33, thereby 
selectively inhibiting FIIa formation rather than FIIa activity. The efficacy of fondaparinux in our model was 
demonstrated with reduced levels of FIIa measured within the SRA of mice administered fondaparinux compared 
to control. The inhibition of AngII-induced aortic aneurysm in mice receiving fondaparinux therefore indicates 
an importance for local FIIa production within the aortic wall (and subsequent activity) in promoting aortic 
aneurysm development in this model.
A subsequent study was performed with the selective FIIa inhibitor, dabigatran. Unexpectedly, the admin-
istration of dabigatran did not have a significant effect on aneurysm growth. Dabigatran is orally available as 
the pro-drug dabigatran etexilate (DE)34, administered in the current study via medicated chow. The dose and 
administration regimen used has been reported to limit atherosclerosis successfully in other models and we con-
firmed that DE administration reduced aortic concentration of FIIa. However we were not able to assess the effect 
of DE on other markers of coagulation. It is therefore possible that dabigatran levels may have been too low to be 
effective. The DE-supplemented chow used in the current study contained the same dose previously reported to 
Figure 3. Effect of fondaparinux on remodelling within the aortic wall in response to AngII. (A) H&E 
micrographs at low magnification (scale bar 500 μ m) of whole transverse section through the SRA showing 
smaller aortic diameter in mice administered fondaparinux (300 μ g/kg/day, s.c.) compared to vehicle for 14 days 
associated with reduced presence of intramural thrombus. The region within the black box corresponds to the 
magnified fields shown in figures B and C. (B) Preserved lamellar pattern of aortic elastin (black after staining 
with the Verhoeff-Van Giesson, (C) in mice administered fondaparinux (300 μ g/kg/day, s.c.) compared to 
vehicle for 14 days (scale bar 50 μ m); *lumen.
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Figure 4. Fondaparinux down-regulated inflammation within the aortic wall in response to AngII. 
Staining for MOMA-2 (monocyte/macrophage) within the SRA of AngII-infused ApoE−/− mice receiving 
fondaparinux (300 μ g/kg/day, s.c.) compared to vehicle control for 14 days. Shown are data expressed as median 
and interquartile range with maximum and minimum data points (whiskers) for positive staining area relative 
to total specimen area (%); *P = 0.032 by Mann-Whitney U test; n = 5 (scale bar 50 μ m).
Figure 5. Effect of FXa on Smad2/3 phosphorylation in human aortic VSMCs in vitro. Dose-dependent 
increase in phosphorylated/total ratio for Smad2/3 in VSMCs exposed to increasing concentrations of FXa 
over 24 hours. Data expressed as median and interquartile range with maximum and minimum data points 
(whiskers) for p-Smad2/3 relative to total Smad2/3 protein; *P < 0.05 by Kruskal-Wallis test with Dunn’s 
multiple comparisons post-hoc; n = 5.
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7Scientific RepoRts | 7:43079 | DOI: 10.1038/srep43079
be effective at producing anticoagulant effects in other rodent models13–17 and was recommended and supplied 
by the manufacturer (Boehringer Ingelheim Pharma GmbH & Co KG, Germany). Moreover, some effects of DE 
administration were demonstrated. For instance, FIIa protein was significantly lower in aortic tissue from mice 
administered DE compared to mice on control diet. These outcomes provide evidence for the action of DE in the 
current mouse model.
It is important to understand that the model used in the current study differed significantly from previous 
investigations of DE, in that it incorporated established vascular disease in which both aortic aneurysm and 
atherosclerosis were induced prior to the commencement of drug administration. The subcutaneous infusion 
of AngII accelerates progression and severity of atherosclerosis and aneurysm within the aorta of ApoE−/− mice 
fed either a standard or high-fat diet30. Previous studies investigating DE in the ApoE−/− model13–17 have done so 
without AngII infusion. The administration period for DE in the current study was 14 days, with the intervention 
initiated 14 days after commencement of AngII infusion. In previous studies, DE has been administered at the 
start of the experiment and continued throughout an extended experimental period of 28–84 days13–17. Finally, 
the mode of DE administration (enteral) was different to that for enoxaparin and fondaparinux (parenteral). 
These differences in study design from previous investigations likely explain our observations.
Based on our mouse model findings, further investigations were focused upon potential mechanisms by 
which fondaparinux inhibited aortic dilatation. The aetiology of AAA is multifactorial with a chronic aortic 
inflammatory response considered central to AAA pathogenesis35. Recent evidence supports a significant role 
of innate immune cells, particularly monocyte/macrophages, in AAA pathogenesis36,37. In the current study, the 
presence of monocyte/macrophages within aortas of mice administered fondaparinux appeared reduced com-
pared to aortas of control mice, suggesting that aortic infiltration by these cells was associated with FXa activity 
within the aortic wall. Indeed, FXa-stimulated Smad phosphorylation has been implicated in promoting inflam-
mation, matrix remodelling and AAA27,38. In this context, the current finding that aortic Smad2/3 activity was 
reduced in AngII-infused mice administered fondaparinux is potentially important.
Studies have suggested that cellular responses to FXa involve the activation of PARs39. Most evidence sug-
gests PAR-2 activation mediates the vascular effects of FXa40. Expression of PAR-2 has been shown to be mark-
edly increased in rodent models of vascular remodelling and human atherosclerosis23–25. Moreover, FXa induces 
PAR-2 expression in human VSMCs and has been reported to enhance PAR-2-mediated cellular oxidative 
stress and inflammation in vessel injury models26. Here we report increased expression of PAR-2 within aor-
tic tissue of ApoE−/− mice in response to AngII and that FXa-induced Smad2/3 phosphorylation (activity) in 
VSMC in vitro is PAR-2 sensitive. In addition, PAR-2 gene expression within the SRA of AngII-infused mice 
was down-regulated with the administration of fondaparinux. Together, these data suggest a potential mecha-
nism by which fondaparinux acted to suppress an AngII-induced aortic inflammatory response, via inhibition of 
FXa-mediated activation of PAR-2 and down-regulation of Smad2/3.
Upregulation of proteolytic activity within the aorta is believed to be critical in the degeneration of medial 
architecture associated with advanced-stage human AAA41. Compromised matrix repair in the damaged aorta 
associated with the loss of synthetic capability of VSMC due to apoptosis is believed to be important in the evolu-
tion of aneurysm degeneration42. There is evidence however that aortic VSMCs have the potential to directly par-
ticipate in the degenerative process43,44. Human AAA tissue-derived VSMCs exhibit increased elastolytic activity 
compared to VSMCs from non-diseased aortas44. VSMC-derived MMP-2 has been particularly implicated in 
AAA45. Qualitative histological examination of aortic tissue from our mouse model suggested a more conserved 
structure of elastin fibres within the aorta of mice administered fondaparinux compared to vehicle, which may 
be associated with the marked down-regulation in MMP2 gene expression within the artery. Our in vitro studies 
demonstrated that exposure of healthy human VSMCs to FXa resulted in the upregulation of MMP-2, an effect 
abrogated in the presence of a PAR-2, but not a PAR-1, antagonist, thus linking FXa-mediated PAR-2 activation 
with matrix remodelling within the aneurysmal aorta.
Several limitations to this study are highlighted. First, suitably prepared plasma samples for coagulation tests 
were not available. The value of functional tests for coagulation to assess effective delivery of anticoagulants in 
vivo is acknowledged. While a significant effect on aneurysm growth was not observed with direct inhibition of 
n
FXa FXa/PAR1Inh FXa/PAR2Inh
P6 6 6
Protein (RDU/μg protein)
Smad2/3 (P/T ratio) 1.64 (1.50–1.88) 1.57 (1.30–1.75) 1.31 (1.22–1.52)* 0.039
MMP9 0.99 (0.97–1.03) 1.03 (1.01–1.05) 0.96 (0.94–1.01) 0.089
MMP2 1.02 (0.79–1.18) 1.05 (0.97–1.13) 0.36 (0.31–0.44)† 0.003
Gene Expression (relative to GAPDH)
Smad2/3 0.88 (0.80–1.47) 1.01 (0.93–1.59) 0.61 (0.50–0.74)‡ 0.002
MMP9 0.64 (0.58–0.76) 0.52 (0.37–0.67) 0.74 (0.55–0.83) 0.110
MMP2 0.86 (0.75–1.03) 0.81 (0.69–0.93) 0.57 (0.50–0.64)§ 0.001
Table 2. Effect of PAR-1 and PAR-2 blockade on FXa-mediated activation of human VSMCs in vitro over 
24 hours Data expressed as median (interquartile range); PAR1Inh, PAR-1 antagonist (SCH79797); PAR2Inh, 
PAR-2 antagonist (FSLLRY-NH2); P/T ratio, ratio of Phosphorylated Smad2/3-to-Total Smad2/3 protein; P, p-value 
for group comparison by Kruskal-Wallis test; *(P = 0.029), †(P = 0.032), ‡(P = 0.046), and §(P = 0.005) determined 
by Dunn’s post-hoc for multiple comparisons.
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FIIa by dabigatran, the authors accept that without plasma data for the anticoagulants and coagulation tests, con-
clusions around dabigatran efficacy and the importance of FIIa to aortic dilatation in the current model are uncer-
tain. Nevertheless, it is reasonable to assume that reduced FIIa formation within the aortic wall consequent to FXa 
neutralisation is an important factor in the inhibition of aortic aneurysm growth by enoxaparin and fondaparinux 
clearly demonstrated in our mouse model. Second, only one in vivo model of AAA was investigated; however, we 
believe that the AngII-ApoE−/− mouse model is more representative of the clinical situation of established vascu-
lar disease in that it is model of aortic aneurysm that incorporates thrombus formation and atherosclerosis. Third, 
the current intervention period was limited to 14 days. This period was chosen as we wished to examine the effect 
of the interventions on established disease (i.e. already developed aortic aneurysms) induced over a 28-day AngII 
infusion period. We believe this is most relevant to the clinical situation. It is plausible that DE may have inhibited 
aneurysm growth if it was administered over a longer period of time. Finally, conclusions regarding the mecha-
nisms underlying the effect of an intervention using samples from the study end-point have limitations. While 
we present in vitro data in support of in vivo findings, analysis of aortic tissue taken from earlier time points may 
have provided additional mechanistic insight.
In summary, findings of this study suggest an important role for FXa/FIIa in aortic aneurysm growth. 
Down-regulation of aortic PAR-2, Smad2/3 phosphorylation and MMP-2, and reduced monocyte/macrophage 
infiltration were demonstrated in a mouse model of aortic aneurysm following administration of the anticoag-
ulant fondaparinux. In vitro, FXa stimulated release of PAR-2-mediated MMP-2 from human aortic VSMC. The 
study identifies a potential for anticoagulants targeting FXa/FIIa in limiting aortic expansion in patients with 
AAA. Assessment of new generation direct FXa inhibitors that potentially offer more favourable efficacy, safety 
profile, and more convenient therapy, for AAA growth is warranted. Conclusions regarding the effect of direct 
FIIa inactivation on aneurysm growth cannot be drawn from the current study and requires further investigation.
Methods
FXa and FIIa inhibitors. Fondaparinux sodium was kindly provided by Alchemia Limited, Australia. Chow 
supplemented with dabigatran etexilate (DE) and matched vehicle was kindly supplied by Boehringer Ingelheim 
Pharma GmbH & Co KG, Germany. Enoxaparin was purchased from Sanofi-aventis.
Mouse model. The use of animals for this work conformed to the Guide for the Care and Use of Laboratory 
Animals (National Institutes of Health, USA). Approval for the mouse studies and experimental work performed 
was obtained from and in accordance with the James Cook University Animal Ethics Committee (A1480). Male 
ApoE−/− mice (obtained from Animal Resources Centre, Western Australia) were housed under a 12:12 hour 
light-dark cycle (relative humidity: 55–60%; temperature: 22 ± 1 °C) and were given standard chow and water ad 
libitum. AAA was induced in 13 week-old male ApoE−/− mice by subcutaneous infusion of AngII (1.0 μ g/kg/min) 
for 28 days, as previously described44,46. Interventions were initiated 14 days into the AngII infusion period, at 
which point surviving mice were stratified to vehicle or anticoagulant based upon aortic ultrasound measure-
ment, whereby median and interquartile range SRA diameter were similarly matched between the two groups. 
Interventions were administered every two days starting at day 15. Five separate studies were performed:
i Association of aortic FXa with AAA severity and effect of AngII infusion on aortic PAR-2 receptor expression. In 
a pilot study, SRA protein was sampled from 8 mice that had received AngII infusion for 28 days. These sam-
ples were selected from mice that had a varying response to AngII infusion with SRA diameter ranging from 
0.95–2.76 mm. SRA levels of FXa were measured by Western blotting and correlated with SRA diameter. The 
level of PAR-2 in aortic protein from an additional 12 mice infused with either AngII (n = 6) or saline (n = 6) 
for 28 days was also determined by Western blotting.
ii Effect of enoxaparin on AAA growth. Forty mice had AAA induced by AngII infusion and at day 14 surviving 
mice were randomly allocated to vehicle (n = 16) or enoxaparin (4.5 IU (2 mg/kg); n = 16) via subcutaneous 
injection every other day for an additional 14 days.
iii Effect of dabigatran on AAA growth. Thirty mice had AAA induced by AngII infusion and at day 14 surviving 
animals were randomly allocated to vehicle (n = 11) or intervention chow (7.5 mg DE/gram chow; n = 13) 
for an additional 14 days. The therapeutic efficacy of the medicated chow has been demonstrated in previous 
mouse studies13–17.
iv Effect of fondaparinux on AAA growth. Thirty mice had AAA induced by AngII infusion and at day 14 surviv-
ing animals were randomly allocated to receive vehicle (n = 11) or fondaparinux (300 μ g/kg; n = 13) via daily 
subcutaneous injection for an additional 14 days.
Assessment of AAA severity. Maximum diameter of the abdominal aorta within the suprarenal region 
was estimated using ultrasound immediately before commencing and then at days 14 and 28 after starting AngII - 
infusion. Mice were immobilized by intraperitoneal injection of ketamine (40 mg/kg) and xylazine (4 mg/kg). 
Ultrasound was performed in B-mode using a MyLa 70 VETXY platform (Esaote, Genoa, Italy) with an LA435 
linear transducer (Esaote) at an operating frequency of 12 MHz. Maximum SRA diameter was measured at peak 
systole using the calliper measurement feature as previously described by our group (1,4). At termination, mice 
were euthanized by CO2 asphyxiation and PBS-perfused dissected aortas (ascending aorta to iliac bifurcation) 
were placed on a graduated template and digitally photographed (Coolpix 4500, Nikon). The maximum diameter 
of the aortic arch (aortic valve to the left subclavian artery), thoracic aorta (TA; arch to the diaphragm), SRA, and 
infrarenal aorta (IRA) were determined from the images using computer-aided analysis (Adobe®Photoshop® 
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CS5 Extended version 12, Adobe Systems Incorporated) as previously reported (1). We have previously demon-
strated that both ultrasound and morphometry diameters have good inter-observer reproducibility46,47.
Atherosclerosis quantification. Sudan IV staining was performed on aortic arch samples to identify inti-
mal atherosclerosis as previously described46. In brief, aortic arches were opened longitudinally and fixed in 75% 
ethanol for 15 minutes. Samples were then stained with Sudan IV solution (0.1% Sudan IV dissolved in equal 
parts acetone and 70% ethanol) for 10 minutes followed by a 15 minutes 80% ethanol wash. Stained aortic arches 
were digitally photographed and intimal atherosclerosis areas were measured using computer aided analysis 
(Adobe Photoshop, USA). We have previously reported good reproducibility of these methods46.
Assessment of aortic proteins. Sample from the SRA were homogenized in the presence of protease 
inhibitors to obtain protein extracts. Protein concentrations were determined using a Bradford protein assay 
kit (BioRad, USA) and used for Western blotting or activity assays. For Western blotting samples (25 μ g of pro-
tein per lane) were separated on a 10% SDS-polyacrylamide electrophoresis gel at 110 volts for 90 minutes then 
transferred (15 mA, 60 min) to polyvinylidene difluoride membrane (BioRad, USA). Non-reducing conditions 
were used for FX/FXa blots. The membrane was blocked with 5% non-fat dry milk for 60 min prior to incuba-
tion with primary antibodies to FX/FXa (1:1000; Haematologic Technologies Inc., #AMX-9050), PAR-2 (1:1000; 
Santa Cruz Biotechnology, S-19, #sc-8207), Smad2/3 (1:1000, Santa Cruz Biotechnology, E-20, #sc-6033), or 
phosphorylated (p)Smad2/3 (1:1000; Santa Cruz Biotechnology, Ser 423/425, #sc-11769-R), overnight at 4 °C. 
HRP-conjugated IgG (1:1000; DakoCytomation) was used to detect the binding of corresponding primary anti-
body. Membranes were stripped and re-blotted with anti-GAPDH antibody (1:5000; Cell Signalling, 14C10, 
#2118) to verify equal loading of protein in each lane. Protein expression was estimated with Western Lightning 
Chemiluminescence Reagent Plus (PerkinElmer Life Sciences, #NEL103001EA) and quantified by Quantity One 
software (v 4.6.7; BioRad, USA). Factor X activity (FXa) was determined using the ACTICHROME® Factor X 
chromogenic activity assay (American Diagnostica Inc., #880) as per manufacturer’s instructions.
Histology. SRA segments were collected at the end of experiments into optimal cutting compound 
(ProSciTech), frozen in cold isopentane (Sigma) and stored in −80 °C until required. The renal arteries were used 
as a landmark to position the tissue and serial sections were taken from the renal arteries to the region of maxi-
mal dilatation. Five SRAs were randomly selected from the vehicle, fondaparinux, and dabigatran groups using 
an online random number generator (https://www.random.org/). Four serial sections of 6 μ M thickness were 
placed on poly-L-lysine coated slides, air dried and subsequently fixed in acetone for 10 min at − 20 °C. Adjacent 
sections were stained with hematoxylin (Polysciences Inc., #24245) and eosin (Polysciences Inc., #09859) (H&E) 
and mounted in Entellan mounting medium (Electron Microscopy Sciences, #14800) to assess gross morphology. 
Verhoeff Van Giessen (VVG) staining (Polysciences Inc., #25089) was performed to assess the integrity of SRA 
elastin. Sections stained with H&E and VVG were photographed using a Nikon Eclipse 50i microscope fitted with 
a CCD Camera (DSFi1). Digital images were captured to a PC supported with NIS Elements (version F2.30) and 
analysed as previously described42. Histological evaluations were carried out in a blinded fashion in 3–4 sections 
per sample (mean coefficient of variation (CV) = 2.97%; n = 5).
Immunohistochemistry. Five SRAs were randomly selected from the vehicle, fondaparinux, and dab-
igatran groups using an online random number generator (https://www.random.org/) from which serial 6 μ M 
thick cryostat sections were obtained. Briefly, four serial sections were placed on silane-coated slides, were air 
dried and then fixed in acetone for 10 min at − 20 °C. Before processing, the sections were rehydrated with PBS 
and incubated in 3% H2O2/0.1% sodium azide/PBS to block endogenous peroxidase. Slides were then incu-
bated in 2% normal goat serum (Vector Laboratories Inc., #S1000) in PBS and endogenous avidin and biotin 
blocked using a commercial kit (Vector Laboratories Inc., #SP2001), and incubated with anti-monocyte and 
macrophage antibody (1:200; MOMA-2, abcam, #ab33451) overnight at 4 °C. Sections were rinsed twice in PBS 
then incubated with biotinylated anti-rat IgG (1:100; Vector Laboratories Inc., #BA-9400) to detect binding of 
the primary antibody. Sections were washed twice in PBS and incubated in peroxidise-avidin-biotin for 30 min 
(Vectastain ABC Elite reagent; Vector Laboratories Inc, #PK6100). Slides were incubated in the peroxidase sub-
strate 3,3′ -diamminobenzidine (ImmPACT DAB; Vector Laboratories Inc, #SK4105), counterstained in Mayer’s 
Haematoxylin, dehydrated, cleared in xylene and mounted in Entellan mounting medium (Electron Microscopy 
Sciences, #14800). Staining of all sections was performed simultaneously using identical reagents and incubation 
times to avoid batch-to-batch variations. Negative controls were included to identify antibody specificity (omit-
ting primary antibody; see Supplementary Fig. S7). Sections were photographed using a Nikon microscope fitted 
with a CCD Camera (Diagnostic Instruments, Inc., USA) and Nikon software (BioRad, USA). Identical exposure 
times and settings were used for all sections. Image analysis was performed on digital tiff images using Adobe 
Photoshop CS5 Extended software. For each section, the total tissue area and area of staining were measured 
using the “Selection Tool” and “Record Measurements” functions. Staining was expressed as a percentage of 
total tissue area (i.e. area macrophage staining/total tissue area × 100). Intra-observer reproducibility was good 
(CV = 2.68%; n = 5).
Cell culture. Human aortic VSMCs (Lonza) were maintained in DMEM in T75 flasks at 37 °C in a humidified 
5% CO2 atmosphere at a density of 2 × 105–1 × 106 cells/ml (passage 5–8). For experiments, VSMCs were seeded 
at 5 × 104 cells/ml and rendered quiescent for 24 hour by incubation in serum-free medium prior to stimulation. 
VSMCs were exposed to increasing FXa concentration (0, 5, 15 and 30 nM) over 24 hours. In a follow up experi-
ment, the effect of PAR-1 or PAR-2 antagonist (10 μ M) on FXa (30 nM)-mediated Smad2/3 phosphorylation and 
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PAR-2 blockade on MMP-2/9 over 24 hours was examined. Proteins prepared from cell lysates were assayed by 
Western blotting and zymography for cellular total- and phosphor-smad2/3, and MMP2/9, respectively.
Zymography. Measurement of MMP2 and MMP9 in conditioned cell culture medium using gelatin zymog-
raphy was performed as previously described43,44. Equal-volume samples were run at room temperature on a 
10% acrylamide-SDS gel containing 0.5% gelatin. Following several washes in 2.5% (vol/vol) Triton X-100, gels 
was incubated for 12 hours at 37 °C in 50 m MTris (pH 8) containing 5 mM CaCl2. Bands were visualized in a 
10% ethanol/10% acetic acid solution after staining with 0.5% Coomassie blue (R-250), with enzyme activity 
semi-quantified with densitometric analysis using the ChemiDoc™ imaging system (Bio-Rad Laboratories) and 
QuantityOne™ 1-D Analysis Software (Bio-Rad Laboratories).
Real time PCR. QuantiTect® Primer Assays were used to determine gene expression for Par-1 (QT00119812), 
Par-2 (QT02255330), Mmp2 (QT00116116), and Mmp9 (QT00108815) in mouse aortic tissue, and, SMAD2 
(QT00004207), SMAD3 (QT00008729), MMP2 (QT00088396) and MMP9 (QT00040040) in human VSMCs 
using quantitative real time (qPCR) as previously described48. The relative expression of these genes in experi-
mental and control samples was calculated by using the concentration-Ct-standard curve method and normal-
ized using the average expression of glyceraldehyde-3-phosphate dehydrogenase (mouse Gapdh, QT01658692; 
human GAPDH, QT00079247) for each sample using the Rotor-Gene Q operating software version 2.0.24. The 
QuantiTect SYBR® Green one-step RT-PCR Kit (Qiagen) was used according to the manufacturer’s instructions 
with 40ng of total RNA as template. All reactions were independently repeated in duplicate to ensure the repro-
ducibility of the results. For mouse studies, six SRAs were randomly selected from the vehicle, fondaparinux, and 
DE groups using an online random number generator (https://www.random.org/).
Statistical Analyses. Data were analysed using GraphPad Prism (version 5) and TIBCO Spotfire S+ (ver-
sion 8.2). D’Agostino and Pearson test was used to test the normality of the data and parametric or non-parametric 
tests applied appropriate to data distribution. Comparison of end-point data (Sudan IV staining, WB, IHC) was 
performed using Mann-Whitney U test. The relationship between AAA severity (diameter) and aortic con-
centration of FX, FXa, FIIa, and fibrin in angII-infused mice was tested using Pearson correlation (r) coeffi-
cient. Aortic end-point data for maximum diameter was compared between vehicle and intervention groups by 
Mann-Whitney U test. Mouse data obtained as a function of time (SRA ultrasound) was compared within each 
group by repeat measures one-way ANOVA, and between vehicle and intervention groups by mixed-effects linear 
regression. In vitro data obtained as a function of concentration or multiple (> 2) intervention conditions was 
compared using Kruskal-Wallis test or ANOVA with Dunn’s or Bonferroni’s multiple comparisons test, respec-
tively, appropriate to data distribution. In all cases P values less than 0.05 were considered significant.
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